Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease COPD Clear all
Completed No phase listed Observational

Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)

NCT01419158
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Alpha-1 Foundation
Other
Eligibility
18 Years and older
Enrollment
3,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
18
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 19, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD

NCT02454959
View directory record Official record
Conditions
COPD
Interventions
GFF MDI (PT003) with Aerochamber, GFF MDI (PT003) without Aerochamber
Device
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 19, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

NCT05166889
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
36
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 19, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02164513
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
10,355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
269
States / cities
Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 226 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 19, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Respiration Rate Monitoring in COPD Patients

NCT03030313
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Reassure Non-Contact Respiration Monitor
Device
Lead sponsor
ResMed
Industry
Eligibility
35 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 19, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02105974
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate/Vilanterol, Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 19, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

Promoting Physical Activity in Chronic Obstructive Pulmonary Disease (COPD) Through New Technology and Health Coaching

NCT01217710
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Physical Activity
Interventions
Activity monitor/smartphone health coaching
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 19, 2026, 5:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Natural History of Gene Expression in the Lung Cells of Non-Smokers, Smokers and Ex-Smokers in Health and Disease

NCT00974064
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Chronic Bronchitis, Emphysema
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 19, 2026, 5:50 AM EDT
Completed No phase listed Observational Results available

Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study

NCT04926233
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium bromide + Olodaterol, Sp(t)iolto® Respimat®
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,371,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 19, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

NCT01854658
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005), Placebo
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
113
States / cities
Birmingham, Alabama • Florence, Alabama • Jasper, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 19, 2026, 5:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prevalence of Chronic Airway Obstruction in Subjects With a History of Cigarette Smoking in a Primary Care Setting

NCT01013948
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Non-Interventional
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 87 Years
Enrollment
1,574 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
40
States / cities
Adamsville, Alabama • Foothill Ranch, California • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Oct 19, 2026, 5:50 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

NCT03307512
View directory record Official record
Conditions
Safety and Tolerability
Interventions
inhaled human insulin, Insulin Lispro (Humalog U-100)
Drug
Lead sponsor
Dance Biopharm Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 19, 2026, 5:50 AM EDT
Active, not recruiting Not applicable Interventional

Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease

NCT05119556
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Video Telehealth Pulmonary Rehabilitation
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Chicago, Illinois • Iowa City, Iowa + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)

NCT05237505
View directory record Official record
Conditions
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Overlap Syndrome
Interventions
bi-level positive pressure non invasive ventilation, Oxygen gas
Device · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 19, 2026, 5:50 AM EDT
Enrolling by invitation No phase listed Observational

Study on Home Obstructive Respiratory Exacerbations

NCT06544928
View directory record Official record
Conditions
COPD Exacerbation, COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection, COPD Exacerbation Acute, COPD
Interventions
RESP™ Biosensor
Device
Lead sponsor
Strados Labs, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 19, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

NCT00206167
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Budesonide/formoterol pMDI, Formoterol Turbuhaler
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
131
States / cities
Birmingham, Alabama • Huntsville, Alabama • Jasper, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 19, 2026, 5:50 AM EDT
Terminated Not applicable Interventional

Environment Effect on Six-Minute Walk Test Performance

NCT02502201
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Alpha-1 Antitrypsin Deficiency
Interventions
six-minute walk study indoors, six-minute walk study outdoors
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 19, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD

NCT01039675
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
500mcg/25mcg once daily, Placebo once daily
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Chester, South Carolina • Gaffney, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 19, 2026, 5:50 AM EDT
Not listed Not applicable Interventional

Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

NCT04677465
View directory record Official record
Conditions
Chronic Bronchitis
Interventions
RheOx Bronchial Rheoplasty, Sham Procedure
Device
Lead sponsor
Gala Therapeutics, Inc.
Industry
Eligibility
35 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 19, 2026, 5:50 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)

NCT04901455
View directory record Official record
Conditions
COPD
Interventions
LAIV
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 19, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Healthy Mediation Adherence To Transform and Effectively Relieve Symptoms

NCT04656093
View directory record Official record
Conditions
COPD, Diabetes, Hypertension
Interventions
Supportive counseling, Education on SMB, Psychoeducation on ATs for maladaptive beliefs (if applicable), Psychoeducation on emotional response (if applicable)
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 19, 2026, 5:50 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Effect of Steroids on Gene Expression in the Healthy Smokers Lungs

NCT00532584
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Beclomethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 19, 2026, 5:50 AM EDT
Completed No phase listed Observational Results available

An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease

NCT03040674
View directory record Official record
Conditions
COPD, Interstitial Lung Disease
Interventions
Cell therapy
Procedure
Lead sponsor
Lung Institute
Industry
Eligibility
16 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 19, 2026, 5:50 AM EDT
Terminated Phase 3 Interventional Results available

Pulmonary Rehabilitation Before Lung Cancer Resection

NCT02887521
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Chronic Obstructive Pulmonary Disease (COPD)
Interventions
education, rehabilitation, pedometer, surgery
Other · Procedure · Device
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Jacksonville, Florida • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 19, 2026, 5:50 AM EDT